Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1D-LSD
- Development stage
- Preclinical
- Lead developer
- Lizard Labs
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
1D-LSD is a psychotropic research chemical and a derivative of lysergic acid diethylamide (LSD). It is believed to act as a prodrug for LSD, meaning it is metabolized in the body to produce LSD and thus exerts similar psychedelic effects. The compound has been used primarily in research settings and as a legal alternative to LSD in some jurisdictions. Its mechanism of action is presumed to be similar to that of LSD, which acts mainly as an agonist at serotonin receptors, particularly the 5-HT2A receptor[2].
02
Targets
HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on 1D-LSD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1D-LSD.